LUCD
Lucid Diagnostics Inc (LUCD)
Healthcare • NASDAQ • $1.03-1.90%
- Symbol
- LUCD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $1.03
- Daily Change
- -1.90%
- Market Cap
- $201.11M
- Trailing P/E
- N/A
- Forward P/E
- -5.72
- 52W High
- $1.70
- 52W Low
- $0.95
- Analyst Target
- $4.10
- Dividend Yield
- N/A
- Beta
- 1.10
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Company websiteResearch LUCD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.